-
1
-
-
84882977045
-
Genetics and biomarkers in personalisation of lung cancer treatment
-
Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 2013; 382: 720-731.
-
(2013)
Lancet
, vol.382
, pp. 720-731
-
-
Rosell, R.1
Bivona, T.G.2
Karachaliou, N.3
-
2
-
-
84857502654
-
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
-
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13: 239-246.
-
(2012)
, vol.13
, pp. 239-246
-
-
Rosell, R.1
Carcereny, E.2
Gervais, R.3
Vergnenegre, A.4
Massuti, B.5
Felip, E.6
-
3
-
-
34547638047
-
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
-
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007; 448: 561-566.
-
(2007)
Nature
, vol.448
, pp. 561-566
-
-
Soda, M.1
Choi, Y.L.2
Enomoto, M.3
Takada, S.4
Yamashita, Y.5
Ishikawa, S.6
-
4
-
-
77953291664
-
The biology and treatment of EML4-ALK non-small cell lung cancer
-
Sasaki T, Rodig SJ, Chirieac LR, Jänne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer 2010; 46: 1773-1780.
-
(2010)
, vol.46
, pp. 1773-1780
-
-
Sasaki, T.1
Rodig, S.J.2
Chirieac, L.R.3
Jänne, P.A.4
-
5
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010; 363: 1693-1703.
-
(2010)
, vol.363
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
Shaw, A.T.4
Solomon, B.5
Maki, R.G.6
-
6
-
-
80051780280
-
Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005
-
Crino L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): profile 1005. ASCO Meet Abstr 2011; 29: 7514.
-
(2011)
, vol.29
, pp. 7514
-
-
Crino, L.1
Kim, D.2
Riely, G.J.3
Janne, P.A.4
Blackhall, F.H.5
Camidge, D.R.6
-
7
-
-
84866934606
-
Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study
-
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALKpositive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012; 13: 1011-1019.
-
(2012)
, vol.13
, pp. 1011-1019
-
-
Camidge, D.R.1
Bang, Y.J.2
Kwak, E.L.3
Iafrate, A.J.4
Varella-Garcia, M.5
Fox, S.B.6
-
8
-
-
69949186250
-
Screening for epidermal growth factor receptor mutations in lung cancer
-
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361: 958-967.
-
(2009)
, vol.361
, pp. 958-967
-
-
Rosell, R.1
Moran, T.2
Queralt, C.3
Porta, R.4
Cardenal, F.5
Camps, C.6
-
9
-
-
69949162760
-
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma
-
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947-957.
-
(2009)
, vol.361
, pp. 947-957
-
-
Mok, T.S.1
Wu, Y.L.2
Thongprasert, S.3
Yang, C.H.4
Chu, D.T.5
Saijo, N.6
-
10
-
-
79959954030
-
Irreversible protein kinase inhibitors
-
Garuti L, Roberti M, Bottegoni G. Irreversible protein kinase inhibitors. Curr Med Chem 2011; 18: 2981-2994.
-
(2011)
, vol.18
, pp. 2981-2994
-
-
Garuti, L.1
Roberti, M.2
Bottegoni, G.3
-
11
-
-
84858669035
-
Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence
-
Ou SH. Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence. Crit Rev Oncol Hematol 2012; 83: 407-421.
-
(2012)
, vol.83
, pp. 407-421
-
-
Ou, S.H.1
-
12
-
-
84877660788
-
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model
-
Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, et al. Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model. Mol Cancer Ther 2013; 12: 589-597.
-
(2013)
, vol.12
, pp. 589-597
-
-
Ninomiya, T.1
Takigawa, N.2
Ichihara, E.3
Ochi, N.4
Murakami, T.5
Honda, Y.6
-
13
-
-
84884736973
-
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations
-
Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327-3334.
-
(2013)
, vol.31
, pp. 3327-3334
-
-
Sequist, L.V.1
Yang, J.C.2
Yamamoto, N.3
O'Byrne, K.4
Hirsh, V.5
Mok, T.6
-
14
-
-
84904692834
-
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUXLung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT)
-
abstr 8004.
-
Yang JC, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, et al. Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUXLung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT). J Clin Oncol 2014; 32: abstr 8004.
-
(2014)
, vol.32
-
-
Yang, J.C.1
Sequist, L.V.2
Schuler, M.H.3
Mok, T.4
Yamamoto, N.5
O'Byrne, K.J.6
-
15
-
-
84877291745
-
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis
-
Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, et al. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst 2013; 105: 595-605.
-
(2013)
, vol.105
, pp. 595
-
-
Lee, C.K.1
Brown, C.2
Gralla, R.J.3
Hirsh, V.4
Thongprasert, S.5
Tsai, C.M.6
-
16
-
-
79953118839
-
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors
-
Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 2011; 3: 75ra26.
-
(2011)
, vol.3
-
-
Sequist, L.V.1
Waltman, B.A.2
Dias-Santagata, D.3
Digumarthy, S.4
Turke, A.B.5
Fidias, P.6
-
17
-
-
84904679830
-
Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebocontrolled METLung (OAM4971g) global trial
-
abstr 8000.
-
Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebocontrolled METLung (OAM4971g) global trial. J Clin Oncol 2014; 32: abstr 8000.
-
(2014)
, vol.32
-
-
Spigel, D.R.1
Edelman, M.J.2
O'Byrne, K.3
Paz-Ares, L.4
Shames, D.S.5
Yu, W.6
-
18
-
-
84898726862
-
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial
-
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, et al. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial. Clin Cancer Res 2014; 20: 2001-2010.
-
(2014)
, vol.20
, pp. 2001-2010
-
-
Costa, C.1
Molina, M.A.2
Drozdowskyj, A.3
Giménez-Capitán, A.4
Bertran-Alamillo, J.5
Karachaliou, N.6
-
19
-
-
84877146688
-
EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced nonsmall cell lung cancer: a case-control study of overall survival
-
Faehling M, Eckert R, Kamp T, Kuom S, Griese U, Sträter J, et al. EGFR-tyrosine kinase inhibitor treatment beyond progression in long-term Caucasian responders to erlotinib in advanced nonsmall cell lung cancer: a case-control study of overall survival. Lung Cancer 2013; 80: 306-312.
-
(2013)
Lung Cancer
, vol.80
, pp. 306-312
-
-
Faehling, M.1
Eckert, R.2
Kamp, T.3
Kuom, S.4
Griese, U.5
Sträter, J.6
-
20
-
-
84867405669
-
Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation
-
Kim SM, Kwon OJ, Hong YK, Kim JH, Solca F, Ha SJ, et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther 2012; 11: 2254-2264.
-
(2012)
, vol.11
, pp. 2254-2264
-
-
Kim, S.M.1
Kwon, O.J.2
Hong, Y.K.3
Kim, J.H.4
Solca, F.5
Ha, S.J.6
-
21
-
-
84887977876
-
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC
-
Walter AO, Sjin RT, Haringsma HJ, Ohashi K, Sun J, Lee K, et al. Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov 2013; 3: 1404-1415.
-
(2013)
, vol.3
, pp. 1404-1415
-
-
Walter, A.O.1
Sjin, R.T.2
Haringsma, H.J.3
Ohashi, K.4
Sun, J.5
Lee, K.6
-
22
-
-
84878561867
-
Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer
-
Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, et al. Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013; 6: 563-576.
-
(2013)
, vol.6
, pp. 563-576
-
-
Berardi, R.1
Santoni, M.2
Morgese, F.3
Ballatore, Z.4
Savini, A.5
Onofri, A.6
-
23
-
-
84904657511
-
First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)
-
abstr 8010.
-
Sequist LV, Soria JC, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Clin Oncol 2014; 32: abstr 8010.
-
(2014)
, vol.32
-
-
Sequist, L.V.1
Soria, J.C.2
Gadgeel, S.M.3
Wakelee, H.A.4
Camidge, D.R.5
Varga, A.6
-
24
-
-
84903135828
-
Targeting Resistance in Lung Cancer
-
Targeting Resistance in Lung Cancer. Cancer Discov 2013; 3: OF9.
-
(2013)
, vol.3
, pp. OF9
-
-
-
25
-
-
84904624695
-
Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant nonsmall cell lung cancer (NSCLC)
-
abstr 8009.
-
Janne PA, Ramalingam SS, Yang JC, Ahn MJ, Kim DW, Kim SW, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant nonsmall cell lung cancer (NSCLC). J Clin Oncol 2014; 32: abstr 8009.
-
(2014)
, vol.32
-
-
Janne, P.A.1
Ramalingam, S.S.2
Yang, J.C.3
Ahn, M.J.4
Kim, D.W.5
Kim, S.W.6
-
26
-
-
79959916680
-
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
-
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res 2011; 71: 4494-4505.
-
(2011)
, vol.71
, pp. 4494-4505
-
-
Fan, W.1
Tang, Z.2
Yin, L.3
Morrison, B.4
Hafez-Khayyata, S.5
Fu, P.6
-
27
-
-
84862777672
-
A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
-
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, et al. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 2012; 18: 521-528.
-
(2012)
, vol.18
, pp. 521-528
-
-
Ng, K.P.1
Hillmer, A.M.2
Chuah, C.T.3
Juan, W.C.4
Ko, T.K.5
Teo, A.S.6
-
28
-
-
84876994464
-
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
-
Nakagawa T, Takeuchi S, Yamada T, Ebi H, Sano T, Nanjo S, et al. EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition. Cancer Res 2013; 73: 2428-2434.
-
(2013)
, vol.73
, pp. 2428-2434
-
-
Nakagawa, T.1
Takeuchi, S.2
Yamada, T.3
Ebi, H.4
Sano, T.5
Nanjo, S.6
-
29
-
-
84856891114
-
Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma
-
Dasari VR, Velpula KK, Alapati K, Gujrati M, Tsung AJ. Cord blood stem cells inhibit epidermal growth factor receptor translocation to mitochondria in glioblastoma. PloS one 2012; 7: e31884.
-
(2012)
, vol.7
-
-
Dasari, V.R.1
Velpula, K.K.2
Alapati, K.3
Gujrati, M.4
Tsung, A.J.5
-
30
-
-
84884526416
-
Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11- associated malignancies
-
Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, et al. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11- associated malignancies. Mol Cancer Ther 2013; 12: 1738-1748.
-
(2013)
, vol.12
, pp. 1738-1748
-
-
Yu, B.1
Liu, W.2
Yu, W.M.3
Loh, M.L.4
Alter, S.5
Guvench, O.6
-
31
-
-
0032980574
-
Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway
-
You M, Yu DH, Feng GS. Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol Cell Biol 1999; 19: 2416-2424.
-
(1999)
, vol.19
, pp. 2416-2424
-
-
You, M.1
Yu, D.H.2
Feng, G.S.3
-
32
-
-
4143066760
-
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
-
Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004; 305: 1163-1167.
-
(2004)
Science
, vol.305
, pp. 1163-1167
-
-
Sordella, R.1
Bell, D.W.2
Haber, D.A.3
Settleman, J.4
-
33
-
-
77951760700
-
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations
-
Lazzara MJ, Lane K, Chan R, Jasper PJ, Yaffe MB, Sorger PK, et al. Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res 2010; 70: 3843-3850.
-
(2010)
, vol.70
, pp. 3843-3850
-
-
Lazzara, M.J.1
Lane, K.2
Chan, R.3
Jasper, P.J.4
Yaffe, M.B.5
Sorger, P.K.6
-
34
-
-
84901036169
-
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal
-
Li L, Han R, Xiao H, Lin C, Wang Y, Liu H, et al. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal. Clin Cancer Res 2014; 20: 2714-2726.
-
(2014)
, vol.20
, pp. 2714-2726
-
-
Li, L.1
Han, R.2
Xiao, H.3
Lin, C.4
Wang, Y.5
Liu, H.6
-
35
-
-
33645506849
-
Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor
-
Alvarez JV, Greulich H, Sellers WR, Meyerson M, Frank DA. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006; 66: 3162-3168.
-
(2006)
, vol.66
, pp. 3162-3168
-
-
Alvarez, J.V.1
Greulich, H.2
Sellers, W.R.3
Meyerson, M.4
Frank, D.A.5
-
36
-
-
36849012237
-
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
-
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117: 3846-3856.
-
(2007)
, vol.117
, pp. 3846-3856
-
-
Gao, S.P.1
Mark, K.G.2
Leslie, K.3
Pao, W.4
Motoi, N.5
Gerald, W.L.6
-
37
-
-
77957273623
-
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer
-
Yao Z, Fenoglio S, Gao DC, Camiolo M, Stiles B, Lindsted T, et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc Natl Acad Sci U S A 2010; 107: 15535-15540.
-
(2010)
, vol.107
, pp. 15535-15540
-
-
Yao, Z.1
Fenoglio, S.2
Gao, D.C.3
Camiolo, M.4
Stiles, B.5
Lindsted, T.6
-
38
-
-
84893867951
-
TGF-beta: duality of function between tumor prevention and carcinogenesis
-
Principe DR, Doll JA, Bauer J, Jung B, Munshi HG, Bartholin L, et al. TGF-beta: duality of function between tumor prevention and carcinogenesis. J Nat Cancer Institute 2014; 106: djt369.
-
(2014)
, vol.106
-
-
Principe, D.R.1
Doll, J.A.2
Bauer, J.3
Jung, B.4
Munshi, H.G.5
Bartholin, L.6
-
39
-
-
77954759029
-
Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality
-
Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121: 193-198.
-
(2010)
, vol.121
, pp. 193-198
-
-
Dusso, A.1
Arcidiacono, M.V.2
Yang, J.3
Tokumoto, M.4
-
40
-
-
84900334614
-
A new Lnc in metastasis: long noncoding RNA mediates the prometastatic functions of TGF-β
-
Li W, Kang Y. A new Lnc in metastasis: long noncoding RNA mediates the prometastatic functions of TGF-β. Cancer Cell 2014; 25: 557-559.
-
(2014)
Cancer Cell
, vol.25
, pp. 557-559
-
-
Li, W.1
Kang, Y.2
-
41
-
-
84900316922
-
A long noncoding RNA activated by TGF-β promotes the invasionmetastasis cascade in hepatocellular carcinoma
-
Yuan JH, Yang F, Wang F, Ma JZ, Guo YJ, Tao QF, et al. A long noncoding RNA activated by TGF-β promotes the invasionmetastasis cascade in hepatocellular carcinoma. Cancer Cell 2014; 25: 666-681.
-
(2014)
Cancer Cell
, vol.25
, pp. 666-681
-
-
Yuan, J.H.1
Yang, F.2
Wang, F.3
Ma, J.Z.4
Guo, Y.J.5
Tao, Q.F.6
-
42
-
-
84887447303
-
Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase
-
Miura K, Wakayama Y, Tanino M, Orba Y, Sawa H, Hatakeyama M, et al. Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase. Oncogene 2013; 32: 5292-5301.
-
(2013)
Oncogene
, vol.32
, pp. 5292-5301
-
-
Miura, K.1
Wakayama, Y.2
Tanino, M.3
Orba, Y.4
Sawa, H.5
Hatakeyama, M.6
-
43
-
-
0033761488
-
The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase
-
Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol 2000; 20: 8513-8525.
-
(2000)
, vol.20
, pp. 8513-8525
-
-
Maroun, C.R.1
Naujokas, M.A.2
Holgado-Madruga, M.3
Wong, A.J.4
Park, M.5
-
44
-
-
84882455547
-
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors
-
Gusenbauer S, Vlaicu P, Ullrich A. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene 2013; 32: 3846-3856.
-
(2013)
Oncogene
, vol.32
, pp. 3846-3856
-
-
Gusenbauer, S.1
Vlaicu, P.2
Ullrich, A.3
-
45
-
-
84888646015
-
Tyrosine kinase gene rearrangements in epithelial malignancies
-
Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013; 13: 772-787.
-
(2013)
, vol.13
, pp. 772-787
-
-
Shaw, A.T.1
Hsu, P.P.2
Awad, M.M.3
Engelman, J.A.4
-
46
-
-
84906556036
-
ALK and ROS1 as a joint target for the treatment of lung cancer: a review
-
Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixidó J, Costa C, Borrell JI. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res 2013; 2: 72-86.
-
(2013)
, vol.2
, pp. 72-86
-
-
Puig De La Bellacasa, R.1
Karachaliou, N.2
Estrada-Tejedor, R.3
Teixidó, J.4
Costa, C.5
Borrell, J.I.6
-
47
-
-
79961088497
-
Anaplastic lymphoma kinase in human cancer
-
Barreca A, Lasorsa E, Riera L, Machiorlatti R, Piva R, Ponzoni M, et al. Anaplastic lymphoma kinase in human cancer. J Mol Endocrinol 2011; 47: R11-R23.
-
(2011)
, vol.47
, pp. R11-R23
-
-
Barreca, A.1
Lasorsa, E.2
Riera, L.3
Machiorlatti, R.4
Piva, R.5
Ponzoni, M.6
-
48
-
-
84903466222
-
The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer
-
Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4: 662-673.
-
(2014)
, vol.4
, pp. 662-673
-
-
Friboulet, L.1
Li, N.2
Katayama, R.3
Lee, C.C.4
Gainor, J.F.5
Crystal, A.S.6
-
49
-
-
84896531092
-
Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer
-
Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A 2014; 111: 4233-4238.
-
(2014)
, vol.111
, pp. 4233-4238
-
-
Kelly, L.M.1
Barila, G.2
Liu, P.3
Evdokimova, V.N.4
Trivedi, S.5
Panebianco, F.6
-
50
-
-
84874586164
-
Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods
-
Tuononen K, Sarhadi VK, Wirtanen A, Rönty M, Salmenkivi K, Knuuttila A, et al. Targeted resequencing reveals ALK fusions in non-small cell lung carcinomas detected by FISH, immunohistochemistry, and real-time RT-PCR: a comparison of four methods. Biomed Res Int 2013; 2013: 757490.
-
(2013)
, vol.2013
-
-
Tuononen, K.1
Sarhadi, V.K.2
Wirtanen, A.3
Rönty, M.4
Salmenkivi, K.5
Knuuttila, A.6
-
51
-
-
84908109481
-
A nice problem to have: when ALK inhibitor therapy works better than expected
-
Doebele RC. A nice problem to have: when ALK inhibitor therapy works better than expected. J Thorac Oncol 2014; 9: 433-435.
-
(2014)
, vol.9
, pp. 433-435
-
-
Doebele, R.C.1
-
52
-
-
84896957081
-
Ceritinib in ALK-rearranged non-small-cell lung cancer
-
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014; 370: 1189-1197.
-
(2014)
, vol.370
, pp. 1189-1197
-
-
Shaw, A.T.1
Kim, D.W.2
Mehra, R.3
Tan, D.S.4
Felip, E.5
Chow, L.Q.6
-
53
-
-
84908111630
-
-
East Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation. April
-
Information ZTcP. East Hanover, New Jersey, USA: Novartis Pharmaceuticals Corporation. April 2014.
-
(2014)
Information ZTcP
-
-
-
54
-
-
84877679409
-
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer
-
Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013; 3: 430-443.
-
(2013)
, vol.3
, pp. 430-443
-
-
Sang, J.1
Acquaviva, J.2
Friedland, J.C.3
Smith, D.L.4
Sequeira, M.5
Zhang, C.6
-
55
-
-
84898027006
-
Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain
-
Richards MW, Law EW, Rennalls LP, Busacca S, O'Regan L, Fry AM, et al. Crystal structure of EML1 reveals the basis for Hsp90 dependence of oncogenic EML4-ALK by disruption of an atypical β-propeller domain. Proc Natl Acad Sci U S A 2014; 111: 5195-5200.
-
(2014)
, vol.111
, pp. 5195-5200
-
-
Richards, M.W.1
Law, E.W.2
Rennalls, L.P.3
Busacca, S.4
O'Regan, L.5
Fry, A.M.6
-
56
-
-
84869211206
-
Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer
-
Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012; 18: 6219-6226.
-
(2012)
, vol.18
, pp. 6219-6226
-
-
Tanizaki, J.1
Okamoto, I.2
Okabe, T.3
Sakai, K.4
Tanaka, K.5
Hayashi, H.6
-
57
-
-
84895814426
-
Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation
-
Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, et al. Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. Clin Cancer Res 2014; 20: 1383-1392.
-
(2014)
, vol.20
, pp. 1383-1392
-
-
Yang, J.J.1
Zhang, X.C.2
Su, J.3
Xu, C.R.4
Zhou, Q.5
Tian, H.X.6
-
58
-
-
84899625563
-
The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells
-
Koyama-Nasu R, Haruta R, Nasu-Nishimura Y, Taniue K, Katou Y, Shirahige K, et al. The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells. Oncogene 2014; 33: 2236-2244.
-
(2014)
Oncogene
, vol.33
, pp. 2236-2244
-
-
Koyama-Nasu, R.1
Haruta, R.2
Nasu-Nishimura, Y.3
Taniue, K.4
Katou, Y.5
Shirahige, K.6
-
59
-
-
79954592031
-
Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer
-
Takezawa K, Okamoto I, Nishio K, Jänne PA, Nakagawa K. Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer. Clin Cancer Res 2011; 17: 2140-2148.
-
(2011)
, vol.17
, pp. 2140-2148
-
-
Takezawa, K.1
Okamoto, I.2
Nishio, K.3
Jänne, P.A.4
Nakagawa, K.5
-
60
-
-
84856915008
-
Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells
-
Tanizaki J, Okamoto I, Takezawa K, Sakai K, Azuma K, Kuwata K, et al. Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells. Br J Cancer 2012; 106: 763-767.
-
(2012)
, vol.106
, pp. 763-767
-
-
Tanizaki, J.1
Okamoto, I.2
Takezawa, K.3
Sakai, K.4
Azuma, K.5
Kuwata, K.6
|